

baha WebStation

Polar Capital Funds plc - Biotechnology Fund Class I GBP Distribution Shares / IE00B42P0H75 / A1W70K / Polar

Last 05/16/2024 ¹	Region		Branch		Type of yield
36.13 GBP	Worldwide		Sector Biotech	nology	paying dividend
Polar Capital Funds plc - Bi	otechnology Fund Class I	GBP Distribution Shares		100	Risk key figu
Benchmark: IX Aktien Biotech Benchmark: IX Aktien Biotech	nnologie			90	CDI
					* Mountain-View
			Mar M	70	
	A. NAMANW			60 50	Yearly Perfor
u	N M. M.			40	2023
	NAW	WW		30	% 2022
A A	W. s	MAN	MANNA MA	20	% 2021
		TW		10	2020
		M		0 	2019
2020	2021	2022	2023	2024	

Type of yield		Т	ype				
paying dividend	end Equity Fund						
Risk key figures							
SRI	1	2	3	4	5	6	7
Mountain-View Funds Rating ² EDA ³							
					74		
Yearly Performance							
2023						+9.	33%
2022						+4.	55%
2021						+5.	64%
2020						+36.	48%
2019						+26.	27%

Master data			Conditions			Other figures		
Fund type	Si	ingle fund	Issue surcharge		5.00%	Minimum investmer	nt USE	0 1,000,000.00
Category		Equity	Planned administr.	fee	0.00%	Savings plan		-
Sub category	Sector Biote	echnology	Deposit fees		0.00%	UCITS / OGAW		Yes
Fund domicile		Ireland	Redemption charge	•	0.00%	Performance fee		10.00%
Tranch volume	(05/16/2024) USD 78	3.92 mill.	Ongoing charges		-	Redeployment fee		0.00%
Total volume		-	Dividends			Investment com	ipany	
Launch date	10	0/31/2013						Polar Capital
KESt report funds		Yes	16 Palace Street, SW1E 5JD, Londo				E 5JD, London	
Business year start		01.01.	United Kingo				nited Kingdom	
Sustainability type		-					https://www.pol	arcapital.co.uk
Fund manager	David Pinniger							
Performance	1M	6	M YTD	1Y		2Y 3Y	5Y	Since start
Performance	+2.91%	+24.54	+4.15%	+12.94%	+34.4	6% +26.15%	+90.46%	+169.43%
Performance p.a.	-			+12.90%	+15.9	3% +8.05%	+13.74%	+14.25%
Sharpe ratio	2.05	2.3	37 0.37	0.48	0	.58 0.20	0.42	0.46
Volatility	18.48%	21.85	20.83%	19.03%	21.0	3% 21.53%	23.72%	22.50%
Worst month	-	-6.61	% -6.61%	-6.61%	-6.6	1% -11.43%	-11.43%	-11.43%
Best month	-	15.36	i% 15.36%	15.36%	15.3	6% 15.36%	16.60%	16.60%
Maximum loss	-3.08%	-11.39	-11.39%	-14.64%	-16.8	7% -25.15%	-25.90%	-

Austria, Germany, Switzerland

1 Important note on update status: The displayed date refers exclusively to the calculation of the NAV. 2 The Mountain-View Data Fund Rating calculates a computative ranking for funds using yield, volatility and trend data. For more information visit <u>MVD Funds Rating</u> 3 Displays the Ethical-Dynamical Ratio calculated according to standard criteria. The maximum value is 100. For more information visit <u>EDA</u>

DISCLAIMER: The information on this page are for informational purposes only and should neither an offer to sell nor a solicitation for the purchase of the security or recommendation in favor of the security to be understood, baha GmbH assumes no liability despite thorough searches for the accuracy of the data. Funds data from: www.mountain-view.com. Fact Sheet created by: www.baha.com Created: 05/18/202-



Polar Capital Funds plc - Biotechnology Fund Class I GBP Distribution Shares / IE00B42P0H75 / A1W70K / Polar

Investment strategy

The Fund is broadly diversified across countries, biotechnology sectors and by market-cap (a measure of company size). The Fund may invest in financial derivatives (complex instruments based upon the value of underlying assets) for hedging, to reduce risk, to manage the Fund more efficiently, or to gain exposure to securities in a more efficient way. The Fund is actively managed and uses the NASDAQ Biotechnology Net Total Return Index (EUR) benchmark as a performance target and to calculate the performance fee. The currency of the Fund is US Dollar and the currency of this share class is Euro (EUR). Any income which the Fund generates may be paid out in the form of an annual dividend at the sole discretion of the Directors.

Investment goal

The objective of the Fund is to preserve capital and achieve long term capital appreciation by investing worldwide in the shares of biotechnology, diagnostics and life sciences tools companies.

